Table 2.

Therapies used in patients with autoimmune and inflammatory RMDs.

	GC	cDMARD	bDMARD	Anti-CD20	BLySi	JAKi
All patients with aiRMDs, n = 89	16 (18%)	43 (48%)	35 (39%)	8 (9%)	2 (2%)	1 (1%)
RA, n = 41	3 (7%)	17 (41%)	18 (44%)	4 (10%)	0	1 (2%)
PsA, n = 7	0	2 (29%)	5 (71%)	0	0	0
AxSpa, n = 12	0	1 (8%)	11 (92%)	0	0	0
SLE n = 11	4 (36%)	9 (8%)	0	0	2 (18%)	0
SS n = 4	1 (25%)	4 (100%)	0	0	0	0
IIM n= 1	1 (100%)	1 (100%)	0	1 (100%)	0	0
SSc n = 1	0	0	0	1 (100%)	0	0
LVV, n = 5	3 (60%)	3 (60%)	1 (20%)	0	0	0
AAV, n = 6	3 (50%)	5 (83%)	0	2 (33%)	0	0
Other vasculitis, n = 1	1 (100%)	1 (100%)	0	0	0	0

Data are presented as n (%). AAV, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; aiRMD, autoimmune and inflammatory rheumatic and musculoskeletal disease; AxSpA, axial spondyloarthritis; IIM, idiopathic inflammatory myositis; LVV, large vessel vasculitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus, SS, Sjögren syndrome; SSc, systemic sclerosis; GC, glucocorticoids; cDMARD, conventional DMARD, namely, methotrexate, leflunomide, azathioprine, chloroquine, hidroxychloroquin; bDMARD, biological DMARD, namely, tumor necrosis factor alpha inhibitors (12 patients with RA and 8 patients with AxSpa and 2 patients with PsA), interleukin 17 inhibitors (3 patients with AxSpa and 3 patients PsA), interleukin 6 inhibitors (6 patients with RA and 1 patients with LVV); LySi, BLyS-specific inhibitor, belimumab; JAKi, janus kinase inhibitor.